SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

PHASE3RecruitingINTERVENTIONAL

Enrollment

524

Participants

Timeline

Start Date

November 22, 2024

Primary Completion Date

September 20, 2027

Study Completion Date

March 20, 2028

Conditions

Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG

SHR-A1904

DRUG

Paclitaxel, Docetaxel, Irinotecan

Trial Locations (1)

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY